High CRP level is a modifiable risk factor for chronic migraine

June 14, 2020

A large population-based 11-year long study just published by Norwegian researchers confirmed that an elevated level of an inflammatory marker C-reactive protein (CRP) is associated with an increased risk of developing chronic migraine.

Inflammation is a well-established part of the pathophysiology of migraine. Pro-inflammatory aspects of obesity are thought to underly the correlation between excessive weight and the frequency of migraines. While it is not clear how high CRP leads to chronification of migraines, there are several ways to lower this marker.

CRP is also a well-documented marker of risk for cardiovascular disease. Statins, such as atorvastatin (Lipitor) lower CRP levels independently of their lipid-lowering effect. Metformin is another drug that can lower CRP levels.

There are several ways to lower CRP without drugs including lifestyle changes such as regular exercise, a healthy diet, and moderate alcohol consumption.

A Japanese study of over 2,000 people showed that blood levels of vitamin C are inversely correlated with CRP levels. A review of 12 published studies of the effect of vitamin C on CRP showed that vitamin C lowers CRP levels.

A meta-analysis of 12 published studies showed that vitamin E (alpha-tocopherol or gamma-tocopherol) is another vitamin that lowers CRP levels.

Written by
Alexander Mauskop, MD
Continue reading
June 4, 2026
Research
A New Study of Meat Intake, Genetics, and Brain Health
A newly published Swedish study suggests that the relationship between diet and brain aging may be more genetically specific than previously understood. Researchers followed over 2,000 older adults for up to 15 years and found that higher meat consumption was associated with slower cognitive decline and lower dementia risk, but only in those carrying the APOE E4 genetic variant, the most common hereditary risk factor for Alzheimer's disease. This may be relevant for people with headaches.
Read article
June 3, 2026
News
Keynote address at the 22nd Annual Neuroscience Zappulla Research Day
I was honored to be delivering the keynote address at the 22nd Annual Neuroscience Zappulla Research Day on Wednesday, June 3, at the Hackensack Meridian Neuroscience Institute, JFK University Medical Center in Edison, NJ.
Read article
May 26, 2026
News
Why I Rarely Prescribe Topiramate, and What the New Data Shows
A new real-world study of 661 patients found that 67% stopped taking topiramate within six months, compared to 30% on candesartan. Candesartan also had a higher responder rate. Topiramate is FDA-approved; candesartan is not. The data makes the case for rethinking that priority.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe